Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 144

Sort by

Sort Order Select

Journal Articles

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial

Blood (2025) 146 (25): 3050–3058.

https://doi.org/10.1182/blood.2025030084

Published: 2025

Includes: Supplemental data

Journal Articles

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load

Blood blood.2025030083.

https://doi.org/10.1182/blood.2025030083

Published: 2025

Includes: Supplemental data

Journal Articles

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Blood (2025) 146 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2025-LBA-6

Published: 2025

Journal Articles

Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study

Blood (2025) 146 (Supplement 1): 2282.

https://doi.org/10.1182/blood-2025-2282

Published: 2025

Journal Articles

Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)

Blood (2025) 146 (Supplement 1): 2275.

https://doi.org/10.1182/blood-2025-2275

Published: 2025

Journal Articles

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Enrique Ocio, Aurore Perrot, Jesus San-Miguel, Lionel Karlin, Joaquin Martinez-Lopez, Sara Bringhen, Paula Rodriguez-Otero, Mohamad Mohty, Robert Orlowski, Meletios Dimopoulos, Xavier Leleu, María-Victoria Mateos, Philippe Moreau, Sandrine Macé, Ecrem Kodas, Christine Tekle, Umer Khan, Corina Oprea, Thierry Facon

Blood (2025) 146 (Supplement 1): 2267.

https://doi.org/10.1182/blood-2025-2267

Published: 2025

Journal Articles

Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05)

Blood (2025) 146 (Supplement 1): 368.

https://doi.org/10.1182/blood-2025-368

Published: 2025

Journal Articles

A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a

Blood (2025) 146 (Supplement 1): 367.

https://doi.org/10.1182/blood-2025-367

Published: 2025

Journal Articles

Relative mortality in elderly frail patients with newly diagnosed multiple myeloma: Ad-hoc analysis of the Phase 3 IFM 2017-03 trial compared to population-based data in France and implications for the functional cure concept

Julie Castiaux, Noemie Bigot, Cyrille Hulin, Magaret Macro, Kamel Laribi, Carla Araujo, Gian Matteo Pica, Cyrille Touzeau, Pascal Godmer, Aurore Perrot, Jean-Yves Mary, Jill Corre, Herve Avet-Loiseau, Philippe Moreau, Xavier Leleu, Thierry Facon, Jerome Lambert, Salomon Manier

Blood (2025) 146 (Supplement 1): 498.

https://doi.org/10.1182/blood-2025-498

Published: 2025

Journal Articles

Longitudinal assessments of minimal residual disease in high-risk patients from benefit phase 3 randomized Study of isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isard in newly diagnosed transplant ineligible multiple myeloma. (IFM 2020-05)

Blood (2025) 146 (Supplement 1): 497.

https://doi.org/10.1182/blood-2025-497

Published: 2025

Journal Articles

Elranatamab real-world step-up dosing patterns in relapsed-refractory multiple myeloma patients: Interim analysis Results of the AMbreLA study

Blood (2025) 146 (Supplement 1): 8151.

https://doi.org/10.1182/blood-2025-8151

Published: 2025

Journal Articles

First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.

Blood (2025) 146 (Supplement 1): 5836.

https://doi.org/10.1182/blood-2025-5836

Published: 2025

Journal Articles

Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial

Blood (2025) 146 (Supplement 1): 101.

https://doi.org/10.1182/blood-2025-101

Published: 2025

Journal Articles

Single-cell immune landscape associated with isatuximab, carfilzomib, lenalidomide, and dexamethasone induction efficacy in newly diagnosed myeloma

Mael Penissat-mahaut, Pierre-Paul Axisa, Hélène Daunes, Marine Cuisinier, Marie-véronique Joubert, Céline Mazzotti, Anaïs Schavgoulidze, Stéphane Minvielle, Philippe Moreau, Cyrille Touzeau, Herve Avet-Loiseau, Aurore Perrot, Jill Corre, Ludovic Martinet

Blood (2025) 146 (Supplement 1): 3932.

https://doi.org/10.1182/blood-2025-3932

Published: 2025

Journal Articles

Apixaban pharmacokinetics in newly diagnosed multiple myeloma patients treated in the benefit and isasocut clinical trials: The apixabor/mibapix study

Blood (2025) 146 (Supplement 1): 744.

https://doi.org/10.1182/blood-2025-744

Published: 2025

Journal Articles

The resistec study: Dissecting immune correlates of resistance and response to teclistamab in real-world multiple myeloma

Liliana Lucca, Ossama Kohil, Marine Cuisinier, Marie-véronique Joubert, Nadège Carrié, Anaïs Schavgoulidze, Laure Vincent, Xavier Leleu, Benjamin Hebraud, Jill Corre, Aurore Perrot, Herve Avet-Loiseau, Ludovic Martinet

Blood (2025) 146 (Supplement 1): 918.

https://doi.org/10.1182/blood-2025-918

Published: 2025

Journal Articles

Favorable impact of patient's selection on outcome of Relapsed/Refractory multiple myeloma treated with idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy; Experience in french patients (Super-FENIX): An IFM study from the descar-T registry

Blood (2025) 146 (Supplement 1): 4076.

https://doi.org/10.1182/blood-2025-4076

Published: 2025

Journal Articles

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 4042.

https://doi.org/10.1182/blood-2025-4042

Published: 2025

Journal Articles

Safety results from REALiTAL: A multi-country observational retrospective study of talquetamab in patients with relapsed/refractory multiple myeloma outside of clinical trials

Rakesh Popat, Katarina Uttervall, Aurore Perrot, Hila Magen, Vitaliy Mykytiv, Carmine Liberatore, Elena Zamagni, Matteo Claudio Da Vià, Elisabetta Antonioli, Markus Hansson, Danielle Greer, Peter Hu, Eric Aeby, Krystof Subrt, Nicholas Francella, Diptendu Santra, Natalia Martin Suñe, K. Martin Kortüm

Blood (2025) 146 (Supplement 1): 4573.

https://doi.org/10.1182/blood-2025-4573

Published: 2025

Journal Articles

Adapted physical activity during first line therapy in multiple myéloma : Innovative assessment of physical status during first-line therapy in 22 multiple myeloma patients

Cecile Sonntag Mottier, Joris mallard, Charline Fuseau, mathieu baldacini, Blandine Guffroy, Aurore Perrot, Bruno Lioure, Elise Toussaint, roland schott, elyse HUCTEAU

Blood (2025) 146 (Supplement 1): 5752.

https://doi.org/10.1182/blood-2025-5752

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial

Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Talquetamab, a GPRC5D×CD3 bispecific antibody, in combination with pomalidomide in patients with Relapsed/Refractory multiple myeloma: Updated safety and efficacy results from the Phase 1b monumental-2 study

Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib , lenalidomide and dexamethasone (Isa Sc-VRd) in transplant ineligible newly diagnosed multiple myeloma: Final analysis of the isasocut study (IFM 2022-05)

Efficacy and safety of isa-vrd in elderly patients with or without frailty criteria: Pooled analysis of imroz and phase 1b studies in newly diagnosed multiple myeloma patients

Sustained minimal residual disease (sMRD) negativity in transplant ineligible newly diagnosed multiple myeloma treated with isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isa-rd: 12-24-month data from the phase 3 benefit trial (IFM 2020-05)

A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a

Relative mortality in elderly frail patients with newly diagnosed multiple myeloma: Ad-hoc analysis of the Phase 3 IFM 2017-03 trial compared to population-based data in France and implications for the functional cure concept

Longitudinal assessments of minimal residual disease in high-risk patients from benefit phase 3 randomized Study of isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isard in newly diagnosed transplant ineligible multiple myeloma. (IFM 2020-05)

Elranatamab real-world step-up dosing patterns in relapsed-refractory multiple myeloma patients: Interim analysis Results of the AMbreLA study

First results of the rwe prospective study TEC care (IFM 2023-01) evaluating teclistamab in triple-class exposed relapsed refractory multiple myeloma patients.

Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial

Single-cell immune landscape associated with isatuximab, carfilzomib, lenalidomide, and dexamethasone induction efficacy in newly diagnosed myeloma

Apixaban pharmacokinetics in newly diagnosed multiple myeloma patients treated in the benefit and isasocut clinical trials: The apixabor/mibapix study

The resistec study: Dissecting immune correlates of resistance and response to teclistamab in real-world multiple myeloma

Favorable impact of patient's selection on outcome of Relapsed/Refractory multiple myeloma treated with idecabtagene vicleucel (Ide-cel) chimeric antigen receptor (CAR) T-cell therapy; Experience in french patients (Super-FENIX): An IFM study from the descar-T registry

Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma

Safety results from REALiTAL: A multi-country observational retrospective study of talquetamab in patients with relapsed/refractory multiple myeloma outside of clinical trials

Adapted physical activity during first line therapy in multiple myéloma : Innovative assessment of physical status during first-line therapy in 22 multiple myeloma patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only